Understanding how cancer cells resist death from treatments
Investigating the regulation of cancer cell death by NFE2L1
This study is looking at how a protein called NFE2L1 helps cancer cells survive treatments like immunotherapy and radiation, with the hope of finding new ways to make these cells easier to kill, which could lead to better treatments for patients.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-10997255 on NIH RePORTER |
What this research studies
This research investigates the mechanisms by which cancer cells evade death caused by therapies like immunotherapy and radiation. By focusing on a specific protein called NFE2L1, the project aims to uncover how this protein helps cancer cells resist a type of cell death known as ferroptosis. The goal is to identify new ways to make cancer cells more susceptible to treatment, potentially leading to more effective therapies for patients. The research involves laboratory experiments to analyze cancer cell behavior and responses to various treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancers that are resistant to current therapies, particularly those undergoing immunotherapy or radiation treatment.
Not a fit: Patients with non-cancerous conditions or those whose cancers are already highly responsive to existing treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective cancer treatments that overcome resistance and improve patient survival rates.
How similar studies have performed: Previous research has shown promise in targeting cell death mechanisms in cancer, suggesting that this approach could lead to significant advancements in treatment.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Murray, Magdalena — Stanford University
- Study coordinator: Murray, Magdalena
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.